Spots Global Cancer Trial Database for Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
Official Title: A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer
Study ID: NCT05156892
Conditions
Study Description
Brief Summary: The study's purpose is to understand the effects of a new treatment (suba-itraconazole and tamoxifen) in epithelial ovarian cancer. Who is it for? Patients may be eligible to join this study with ovarian cancer resistant to platinum-based chemotherapy agents Study Details: Participants will receive different doses of tamoxifen and suba-itraconazole to determine the optimal combination dose. Participants will be seen by the investigators once a week for the first 3 weeks and then once every 4 weeks. Participant will be reviewed by a clinician and undergo regular blood tests, cardiac monitoring and imaging assessments.
Detailed Description: A phase 1/2 study of Suba-itraconazole and Tamoxifen in platinum resistant ovarian carcinoma
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia
Contact Details
Name: Anthony Joshua, FRACP, MBBS, PhD
Affiliation: St Vincent's Hospital, Sydney
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
